Skip to main content
Loading

ImBiome Inc.

October 15, 2024
Hunt Room
Platform for Therapeutics
ImBiome Inc.
ImBiome is a Live Bio-therapeutic Products (LBP) platform company with first-in-class antibiotic replacement drug for GI infectious diseases (gastroenteritis). Our products are enabled by a pioneering, proprietary, clinically validated LBP drug design, formulation & delivery technology (LB-Platform(tm)) that optimizes LBP drug bioavailability and functional state. In one analogy, ImBiome’s technology is to LBP sector what lipid nanoparticles became for mRNA-based products – a missing/foundational therapy design & delivery technology that enables consistent clinical and regulatory success and unlocks the multi-billion $ value of the entire new drug class of live bio-therapeutic products. ImBiome is significantly de-risked due to our ability to generate early revenue, large body of clinical evidence to date (50+ studies of products utilizing LB-Platform technology), and established manufacturability (400+ m doses manufactured utilizing the technology). The company is led by a team of experienced leaders with decades of biotech, executive, and entrepreneurial experience with successful exits.
Speakers
Igor Kouzin, Co-founder & Executive Chairman - ImBiome Inc.

DOUBLE HELIX SPONSOR

HELIX SPONSOR

PREMIER SPONSOR

CONFERENCE SPONSORS